June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Establishing a Hybrid Control for Conjunctival Allergen Challenge Studies for Allergic Conjunctivitis
Author Affiliations & Notes
  • Qian H Li
    Statistics and Data Corporation, Arizona, United States
  • Paul J Gomes
    Ora, Inc, Massachusetts, United States
  • Gustavo De Moraes
    Ora, Inc, Massachusetts, United States
    Columbia University, New York, New York, United States
  • Hongyan Li
    Statistics and Data Corporation, Arizona, United States
  • Mark B Abelson
    Ora, Inc, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Qian Li Statistics & Data Corporation, Code E (Employment), Bristol Myers Squibb, Code E (Employment); Paul Gomes Ora, Inc, Code E (Employment); Gustavo De Moraes Ora, Inc, Code E (Employment); Hongyan Li Statistics & Data Corporation, Code E (Employment); Mark Abelson Ora, Inc, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3376 – A0163. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qian H Li, Paul J Gomes, Gustavo De Moraes, Hongyan Li, Mark B Abelson; Establishing a Hybrid Control for Conjunctival Allergen Challenge Studies for Allergic Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3376 – A0163.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Randomized, vehicle-controlled, and double-masked conjunctival allergen challenge (CAC) studies have been successfully used to support marketing applications for treatments of allergic conjunctivitis. These studies have been conducted using standardized challenge methodologies and the endpoints have been evaluated with consistent approach, therefore it may be feasible to use hybrid control arms in future CAC trials. The purpose of hybrid control is to pool the trial control subjects and certain historical control subjects based on adequate statistical matching, such as propensity score (PS). The advantage of using a hybrid control is to expose fewer subjects to allergens for whom there will be no benefit from the vehicle treatment.

Methods : Among three completed Phase II and III CAC studies for the allergic conjunctivitis indication, two are used as historical control and one is selected as a reference. We compare the outcomes between the historical control and the reference trial control, after controlling PS, to evaluate the similarity in vehicle treatment responses. The PS matching incorporates prognostic factors such as age, sex, and baseline post-challenge itchiness and redness. We construct a hybrid control arm for the reference trial using PS matching between the trial treatment group and the historical control. The results of the treatment effect using the hybrid control are compared with the results using the trial control.

Results : The reference study was randomized in a 2:1 ratio to treatment (91 subjects) or control (47 subjects). The combined historical control includes 75 subjects from the two studies. Figure 1 shows the post-challenge mean scores of itchiness and redness for the baseline, 16 hours post treatment time points, and 15-minutes post treatment, displayed by individual study and matched groups using PS matching. The mean differences between the two matched groups are reduced to less than or equal to 0.24. Table 1 shows that the conclusions on treatment effect are unchanged using the hybrid control in the reference trial. The least squares mean differences are less than or equal to 0.17 between the trial and hybrid controls.

Conclusions : Introducing hybrid control arms in CAC studies maintains study integrity and validity. The use of a hybrid control could potentially reduce costs and improve subject safety.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×